Origami Therapeutics

Executive Summary

Origami Therapeutics is a private biotechnology company based in Cambridge, Massachusetts, founded in 2020. The company is focused on developing next-generation, disease-modifying small molecule therapies that target protein degradation and correction, with an initial emphasis on neurodegenerative diseases. By leveraging innovative approaches to protein homeostasis, Origami aims to address the underlying pathophysiology of conditions such as Alzheimer's, Parkinson's, and Huntington's disease. While the company remains in preclinical stages with no disclosed pipeline candidates, its platform technology has potential applicability across multiple indications. The biotech landscape for protein degradation therapies has seen significant interest, and Origami's early-stage positioning suggests it could attract partnership or investment opportunities as it advances toward clinical development.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing65% success
• Q4 2026Lead Candidate Nomination50% success
• Q1 2027IND-Enabling Studies Initiation35% success